Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update

Audrey Thurm, Elaine Tierney, Cristan Farmer, Phebe Albert, Lisa Joseph, Susan Swedo, Simona Bianconi, Irena Bukelis, Courtney Wheeler, Geeta Sarphare, Diane Lanham, Christopher A Wassif, Forbes D Porter, Audrey Thurm, Elaine Tierney, Cristan Farmer, Phebe Albert, Lisa Joseph, Susan Swedo, Simona Bianconi, Irena Bukelis, Courtney Wheeler, Geeta Sarphare, Diane Lanham, Christopher A Wassif, Forbes D Porter

Abstract

Background: Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive inborn error of cholesterol metabolism syndrome with neurocognitive manifestations. SLOS is the result of mutations in the gene encoding the 7-dehydrocholesterol reductase, which results in the elevation of the cholesterol precursor 7-dehydrocholesterol (7-DHC). Previous reports indicate that intellectual disability, behavioral disturbances, and autism symptoms are frequently part of the SLOS behavioral phenotype. In the current study, we characterize the developmental history and current behavior of 33 individuals with SLOS aged 4 to 23 years and report on biomarkers 7-DHC and 8-DHC in relation to cognition and behavior.

Methods: This was an observational case series, wherein participants with SLOS underwent extensive behavioral evaluation of cognitive function, adaptive function, autism symptoms, and problem behaviors, in addition to parent report of developmental milestones. Serum and CSF were contemporaneously obtained from the majority of participants.

Results: Developmental milestones such as walking, talking, and toileting were uniformly delayed. Overall levels of cognitive and adaptive functioning were low; no participant received adaptive behavior scores in the average range, and the mean level of cognitive functioning in the full sample was in the moderate range of impairment. Aggressive behavior was present in nearly half of participants. Although the majority of participants had elevated scores on the gold standard autism diagnostic instruments, only about half of participants received a clinical diagnosis of autism spectrum disorder. Finally, while CSF cholesterol was not found to correlate with cognitive or adaptive functioning, both serum and CSF 7-DHC and 8-DHC (and their ratios with cholesterol) were moderately and negatively correlated with functioning in this group.

Conclusions: A history of developmental delay, followed by intellectual disability, is common in individuals with SLOS. Although autism spectrum disorder appears to be a frequent diagnosis in this population, it is apparent that the low level of functioning observed in SLOS may artificially inflate scores on standard autism assessments. Our findings further support that cholesterol precursors 7-DHC and 8-DHC are important biomarkers of the level of functioning in SLOS, especially regarding cognitive abilities, and thus may be to explore as mediators within the context of treatment trials.

Trial registration: ClinicalTrials.gov, NCT00001721, NCT00064792.

Keywords: Autism; Developmental delay; Smith-Lemli-Opitz; Sterols.

References

    1. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res. 2011;52(1):6–34. doi: 10.1194/jlr.R009548.
    1. Irons M, Elias ER, Salen G, Tint GS, Batta AK. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet (London, England) 1993;341(8857):1414. doi: 10.1016/0140-6736(93)90983-N.
    1. Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, Connor WE, et al. Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet. 1998;63(1):55–62. doi: 10.1086/301936.
    1. Cross JL, Iben J, Simpson CL, Thurm A, Swedo S, Tierney E, et al. Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets. Clin Genet. 2014.
    1. Nowaczyk MJ, Irons MB. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am J Med Genet C: Semin Med Genet. 2012;160c(4):250–62. doi: 10.1002/ajmg.c.31343.
    1. Opitz JM. RSH/SLO (“Smith-Lemli-Opitz”) syndrome: historical, genetic, and developmental considerations. Am J Med Genet. 1994;50(4):344–6. doi: 10.1002/ajmg.1320500408.
    1. Tierney E, Nwokoro NA, Porter FD, Freund LS, Ghuman JK, Kelley RI. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet. 2001;98(2):191–200. doi: 10.1002/1096-8628(20010115)98:2<191::AID-AJMG1030>;2-M.
    1. Fenson L, Dale PS, Reznick JS, Thal D, Bates E, Hartung JP, et al. MacArthur Communicative Development Inventories: user’s guide and technical manual. Singular Publishing Group San Diego, CA; 1993.
    1. Sikora DM, Pettit-Kekel K, Penfield J, Merkens LS, Steiner RD. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2006;140(14):1511–8. doi: 10.1002/ajmg.a.31294.
    1. Rutter M, LeCouteur A, Lord C. Autism Diagnostic Interview-Revised (ADI-R) Los Angeles: Western Psychological Services; 2003.
    1. Lord C, Risi S, Lambrecht L, Cook EH, Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205–23. doi: 10.1023/A:1005592401947.
    1. Gilliam JE. Gilliam Autism Rating Scale. Austin, TX: Pro-ed; 1995.
    1. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1094–103. doi: 10.1097/01.chi.0000227880.42780.0e.
    1. Sappok T, Diefenbacher A, Budczies J, Schade C, Grubich C, Bergmann T, et al. Diagnosing autism in a clinical sample of adults with intellectual disabilities: how useful are the ADOS and the ADI-R? Res Dev Disabil. 2013;34(5):1642–55. doi: 10.1016/j.ridd.2013.01.028.
    1. Freeman KA, Eagle R, Merkens LS, Sikora D, Pettit-Kekel K, Nguyen-Driver M, et al. Challenging behavior in Smith-Lemli-Opitz syndrome: initial test of biobehavioral influences. Cogn Behav Neurol. 2013;26(1):23–9. doi: 10.1097/WNN.0b013e31828bf6d5.
    1. Sparks SE, Wassif CA, Goodwin H, Conley SK, Lanham DC, Kratz LE, et al. Decreased cerebral spinal fluid neurotransmitter levels in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2014;37(3):415–20. doi: 10.1007/s10545-013-9672-5.
    1. Gotham K, Risi S, Pickles A, Lord C. The Autism Diagnostic Observation Schedule: revised algorithms for improved diagnostic validity. J Autism Dev Disord. 2007;37(4):613–27. doi: 10.1007/s10803-006-0280-1.
    1. Roid GH. Standford-Binet Intelligence Scales. Fifth. Itasca: Riverside Publishing; 2003.
    1. Mullen EM, editor. Mullen Scales of Early Learning. Circle Pines: American Guidance Service; 1995.
    1. Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales. 2. Circle Pines: AGS Publishing; 2005.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: American Psychiatric Publishing; 2000.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing; 2013.
    1. Kelley RI, Hennekam RCM. The Smith-Lemli-Opitz syndrome. J Med Genet. 2000;37(5):321–35. doi: 10.1136/jmg.37.5.321.
    1. Moss J, Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res. 2009;53(10):852–73. doi: 10.1111/j.1365-2788.2009.01197.x.
    1. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2(10):909–16. doi: 10.1016/S2215-0366(15)00376-4.
    1. Loesch DZ, Bui QM, Dissanayake C, Clifford S, Gould E, Bulhak-Paterson D, et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev. 2007;31(3):315–26. doi: 10.1016/j.neubiorev.2006.09.007.
    1. Jeste SS, Sahin M, Bolton P, Ploubidis GB, Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol. 2008;23(5):520–5. doi: 10.1177/0883073807309788.
    1. Thurman AJ, McDuffie A, Kover ST, Hagerman RJ, Abbeduto L. Autism symptomatology in boys with fragile X syndrome: a cross-sectional developmental trajectories comparison with nonsyndromic autism spectrum disorder. J Autism Dev Disord. 2015;45(9):2816–32. doi: 10.1007/s10803-015-2443-4.
    1. Srivastava S, Landy-Schmitt C, Clark B, Kline AD, Specht M, Grados MA. Autism traits in children and adolescents with Cornelia de Lange syndrome. Am J Med Genet A. 2014;164a(6):1400–10. doi: 10.1002/ajmg.a.36573.
    1. Bishop SL, Thurm A, Farmer C, Lord C. Autism spectrum disorder (ASD), intellectual disability, and delayed walking. Pediatrics. In press.
    1. Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, et al. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet. 1998;35(7):558–65. doi: 10.1136/jmg.35.7.558.
    1. Powis L, Oliver C. The prevalence of aggression in genetic syndromes: a review. Res Dev Disabil. 2014;35(5):1051–71. doi: 10.1016/j.ridd.2014.01.033.
    1. Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, Kraft HG, Moebius FF, Glossmann H, et al. Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet. 2000;66(2):402–12. doi: 10.1086/302760.
    1. Jira PE, Wanders RJ, Smeitink JA, De Jong J, Wevers RA, Oostheim W, et al. Novel mutations in the 7-dehydrocholesterol reductase gene of 13 patients with Smith--Lemli--Opitz syndrome. Ann Hum Genet. 2001;65(Pt 3):229–36. doi: 10.1046/j.1469-1809.2001.6530229.x.
    1. Wassif CA, Krakowiak PA, Wright BS, Gewandter JS, Sterner AL, Javitt N, et al. Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab. 2005;85(2):96–107. doi: 10.1016/j.ymgme.2004.12.009.
    1. Lee RW, Conley SK, Gropman A, Porter FD, Baker EH. Brain magnetic resonance imaging findings in Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2013;161a(10):2407–19.
    1. Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, et al. Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol. 2015;25(10):1513–31. doi: 10.1016/j.euroneuro.2015.06.009.
    1. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806–15. doi: 10.1161/01.ATV.0000120374.59826.1b.
    1. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem. 2009;390(4):287–93. doi: 10.1515/BC.2009.035.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi